DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Thursday morning. The firm issued a hold rating on the stock.

Several other research firms also recently issued reports on DBVT. JMP Securities restated a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Tuesday, December 10th. HC Wainwright upped their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Up 10.4 %

Shares of NASDAQ DBVT opened at $3.83 on Thursday. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $9.50. The stock has a market capitalization of $78.78 million, a price-to-earnings ratio of -0.85 and a beta of 0.64. The stock’s fifty day simple moving average is $3.29 and its 200 day simple moving average is $3.82.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.